Literature DB >> 15535130

Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type.

Daniel W McKeel1, Joseph L Price, J Philip Miller, Elizabeth A Grant, Chengjie Xiong, Leonard Berg, John C Morris.   

Abstract

Universally accepted neuropathologic criteria for differentiating Alzheimer disease (AD) from healthy brain aging do not exist. We tested the hypothesis that Bielschowsky silver stained total, cored, and neuritic senile plaques (TSPs, CSPs, and NSPs, respectively), rather than neurofibrillary tangles (NFTs), best discriminate between the 2 conditions using rigorously defined nondemented (n = 7) and AD (n = 35) subjects with no known co-morbidities. We compared lesions in 3 neocortical regions, in hippocampal CA1, and in entorhinal cortex in 19 men and 13 women between 74 and 86 years at death. The Clinical Dementia Rating (CDR) was used to assess degree of cognitive impairment within a year of demise. Neocortical TSP measures provided the highest correlation with expiration CDR: area under the curve (AUC) = 0.986 with 97.8% sensitivity at 90% specificity with an estimated cut-point of 6.0 TSP/ mm2. All SP measures yielded higher estimated AUC and sensitivity for 90% specificity compared to NFTs. Derived TSP cut-points applied to 149 persons with clinical AD regardless of their neuropathologic diagnosis yielded a sensitivity of 97% and specificity of 84% for TSPs in the 3 neocortical areas. Thus cut-points based on both diffuse and neuritic SP in neocortical regions distinguished nondemented and AD subjects with high sensitivity and specificity.

Entities:  

Mesh:

Year:  2004        PMID: 15535130     DOI: 10.1093/jnen/63.10.1028

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  21 in total

1.  Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

Authors:  John L Robinson; Felix Geser; Maria M Corrada; Daniel J Berlau; Steven E Arnold; Virginia M-Y Lee; Claudia H Kawas; John Q Trojanowski
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

2.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

3.  Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry.

Authors:  Kebreten F Manaye; Paul C Wang; Jahn N O'Neil; Sophia Y Huang; Tao Xu; De-Liang Lei; Yousef Tizabi; Mary Ann Ottinger; Donald K Ingram; Peter R Mouton
Journal:  Age (Dordr)       Date:  2007-08-03

4.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

5.  What does it take to stay healthy past 100?: Commentary on "No disease in the brain of a 115-year-old woman".

Authors:  Joseph L Price
Journal:  Neurobiol Aging       Date:  2008-06-04       Impact factor: 4.673

6.  A Unified Approach of Meta-Analysis: Application to an Antecedent Biomarker Study in Alzheimer's Disease.

Authors:  Chengjie Xiong; Gerald van Belle; Kejun Zhu; J Philip Miller; John C Morris
Journal:  J Appl Stat       Date:  2011-01-01       Impact factor: 1.404

7.  Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.

Authors:  Timo Grimmer; Susanne Tholen; Behrooz H Yousefi; Panagiotis Alexopoulos; Annette Förschler; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Robert Perneczky; Christian Sorg; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

Review 8.  Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B.

Authors:  Keith A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

9.  Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients.

Authors:  Christoph Zenzmaier; Josef Marksteiner; Andreas Kiefer; Peter Berger; Christian Humpel
Journal:  J Neurochem       Date:  2009-05-11       Impact factor: 5.372

10.  Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity.

Authors:  Peter T Nelson; Gregory A Jicha; Frederick A Schmitt; Huaichen Liu; Daron G Davis; Marta S Mendiondo; Erin L Abner; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.